Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma submits...

    Natco Pharma submits new drug application with USFDA for generic Ibrutinib tablets

    Farhat NasimWritten by Farhat Nasim Published On 2019-02-01T09:30:13+05:30  |  Updated On 1 Feb 2019 9:30 AM IST
    Natco Pharma submits new drug application with USFDA for generic Ibrutinib tablets

    Natco has submitted the application with the US Food and Drug Administration(USFDA) for a generic version of Ibrutinib tablets in the strengths of 140 mg, 280 mg, 420 mg and 560 mg. The tablets would be generic equivalents to Imbruvica tablets.


    New Delhi: Natco pharma Thursday said it has submitted an abbreviated new drug application(ANDA) with the US health regulator for a generic version of Ibrutinib tablets used for treating certain cancers. Natco said the company and its co-development and marketing partner Alvogen Pine Brook LLC, USA, believe that the ANDA is possibly sole first-to-file based on the ANDA filing dates.


    "We further believe that our ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product under certain circumstances," Natco Pharma said in a BSE filing.


    Read Also: Natco Pharma launches Valsartan Sacubitril tablets in India under brand name VALSAC


    Natco has submitted the application with the US Food and Drug Administration(USFDA) for a generic version of Ibrutinib tablets in the strengths of 140 mg, 280 mg, 420 mg and 560 mg. The tablets would be generic equivalents to Imbruvica tablets.


    In the US, Imbruvica brand is owned and marketed by Pharmacyclics LLC and Janssen Biotech Inc. "Imbruvica had US sales of approximately USD 2.6 billion for twelve months ended September 2018, according to data from IQVIA," the company said.


    "As per the last tracked prescription sales, almost 83 per cent of the sales contribution has come from the above-mentioned tablet dosage forms," it added.


    Read Also: Natco Pharma Q2 Profit up 35 per cent to Rs 583 Crore

    Abbreviated New Drug ApplicationAlvogen Pine Brook LLCANDABSEcancer generic drugIbrutinib tabletsIQVIAJanssen BiotechNatco pharmaNatco Pharma sharesUSUS Food and Drug AdministrationUS healthUSAUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok